Horizon Pharma plc Announces 2016 Net Sales and Adjusted EBITDA Guidance; Reviews 2020 Long-Range Plan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Horizon Pharma plc Announces 2016 Net Sales and Adjusted EBITDA Guidance; Reviews 2020 Long-Range Plan

Actimmune and Friedreich's Ataxia Could Help Horizon Pharma (HZNP) Post Upside, Mizuho Says; PT to $34

November 10, 2015 6:57 AM EST

Horizon Pharma (NASDAQ: HZNP) reported 3Q:15 revenue of $226.5M vs. consensus of $193.2M. Adjusted EPS of $0.70 also beat the consensus number of $0.41. The beat was driven by strong product demand (volumes) across all of the company's brands, coupled with lower than expected SG&A expense and... More

Horizon Pharma's (HZNP) FY16 Revenue Guidance Tops Views

November 9, 2015 8:01 AM EST

Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, will host an investor meeting today where for the first time it is providing full-year 2016 net sales and adjusted EBITDA guidance and outlining its long-range plan for its current portfolio of medicines. The Company's presentation will begin... More